{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:18:17Z","timestamp":1795033097754,"version":"4.10.2"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1038\/s41591-025-04057-z","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T22:02:11Z","timestamp":1762466531000},"page":"281-287","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["A meta-analysis of albuminuria as a surrogate endpoint for kidney failure"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-3730","authenticated-orcid":false,"given":"Hiddo J. L.","family":"Heerspink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem H.","family":"Collier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhi","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyuan","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hocine","family":"Tighiouart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald B.","family":"Appel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5830-9663","authenticated-orcid":false,"given":"Fernando","family":"Caravaca-Font\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Floege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Hannedouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enyu","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7454-8376","authenticated-orcid":false,"given":"Tazeen H.","family":"Jafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia B.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9879-8388","authenticated-orcid":false,"given":"Philip K. T.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5084-5130","authenticated-orcid":false,"given":"Bart D.","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon L.","family":"Neuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald D.","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6194-3446","authenticated-orcid":false,"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco P.","family":"Schena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9507-5301","authenticated-orcid":false,"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley A.","family":"Inker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"4057_CR1","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.kint.2019.07.012","volume":"96","author":"KJ Jager","year":"2019","unstructured":"Jager, K. J. et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 96, 1048\u20131050 (2019).","journal-title":"Kidney Int."},{"key":"4057_CR2","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group.","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 105, S117\u2013S314 (2024).","journal-title":"Kidney Int."},{"key":"4057_CR3","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1053\/j.ajkd.2022.03.011","volume":"80","author":"LA Inker","year":"2022","unstructured":"Inker, L. A. et al. Clinical trial considerations in developing treatments for early stages of common, chronic kidney diseases: a scientific workshop cosponsored by the National Kidney Foundation and the US Food and Drug Administration. Am. J. Kidney Dis. 80, 513\u2013526 (2022).","journal-title":"Am. J. Kidney Dis."},{"key":"4057_CR4","unstructured":"FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK338448\/ (National Institutes of Health, 2016)."},{"key":"4057_CR5","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1172\/JCI16079","volume":"111","author":"S Tang","year":"2003","unstructured":"Tang, S. et al. Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo. J. Clin. Invest. 111, 515\u2013527 (2003).","journal-title":"J. Clin. Invest."},{"key":"4057_CR6","first-page":"1179","volume":"13","author":"M Morigi","year":"2002","unstructured":"Morigi, M. et al. Protein overload-induced NF-\u03baB activation in proximal tubular cells requires H2O2 through a PKC-dependent pathway. J. Am. Soc. Nephrol. 13, 1179\u20131189 (2002).","journal-title":"J. Am. Soc. Nephrol."},{"key":"4057_CR7","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1681\/ASN.0000000000000357","volume":"35","author":"A Faivre","year":"2024","unstructured":"Faivre, A. et al. Spatiotemporal landscape of kidney tubular responses to glomerular proteinuria. J. Am. Soc. Nephrol. 35, 854\u2013869 (2024).","journal-title":"J. Am. Soc. Nephrol."},{"key":"4057_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","volume":"7","author":"J Coresh","year":"2019","unstructured":"Coresh, J. et al. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol. 7, 115\u2013127 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"4057_CR9","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/j.1541-0420.2008.01106.x","volume":"65","author":"MM Joffe","year":"2009","unstructured":"Joffe, M. M. & Greene, T. Related causal frameworks for surrogate outcomes. Biometrics 65, 530\u2013538 (2009).","journal-title":"Biometrics"},{"key":"4057_CR10","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","volume":"7","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink, H. J. L. et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 7, 128\u2013139 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"4057_CR11","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2215\/CJN.08600718","volume":"14","author":"A Thompson","year":"2019","unstructured":"Thompson, A. et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin. J. Am. Soc. Nephrol. 14, 469\u2013481 (2019).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"4057_CR12","unstructured":"International Society of Glomerular Disease. PARASOL: proteinuria as clinical trial endpoints in focal segmental glomerulosclerosis https:\/\/www.is-gd.org\/parasol (accessed 9 October 2025)."},{"key":"4057_CR13","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295\u20132306 (2019).","journal-title":"N. Engl. J. Med."},{"key":"4057_CR14","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436\u20131446 (2020).","journal-title":"N. Engl. J. Med."},{"key":"4057_CR15","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","volume":"393","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink, H. J. L. et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 393, 1937\u20131947 (2019).","journal-title":"Lancet"},{"key":"4057_CR16","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41591-023-02418-0","volume":"29","author":"LA Inker","year":"2023","unstructured":"Inker, L. A. et al. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nat. Med. 29, 1867\u20131876 (2023).","journal-title":"Nat. Med."},{"key":"4057_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic, V. et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 391, 109\u2013121 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4057_CR18","doi-asserted-by":"crossref","unstructured":"The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 388, 117\u2013127 (2023).","DOI":"10.1056\/NEJMoa2204233"},{"key":"4057_CR19","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.kint.2020.04.051","volume":"98","author":"J Li","year":"2020","unstructured":"Li, J. et al. Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. Kidney Int. 98, 769\u2013777 (2020).","journal-title":"Kidney Int."},{"key":"4057_CR20","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1681\/ASN.2020050723","volume":"31","author":"M Oshima","year":"2020","unstructured":"Oshima, M. et al. Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: a post hoc analysis from the CREDENCE trial. J. Am. Soc. Nephrol. 31, 2925\u20132936 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"4057_CR21","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.7326\/M23-1023","volume":"176","author":"R Agarwal","year":"2023","unstructured":"Agarwal, R. et al. Impact of finerenone-induced albuminuria reduction on chronic kidney disease outcomes in type 2 diabetes: a mediation analysis. Ann. Intern. Med. 176, 1606\u20131616 (2023).","journal-title":"Ann. Intern. Med."},{"key":"4057_CR22","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","volume":"65","author":"D de Zeeuw","year":"2004","unstructured":"de Zeeuw, D. et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 65, 2309\u20132320 (2004).","journal-title":"Kidney Int."},{"key":"4057_CR23","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.kint.2024.05.024","volume":"106","author":"HJL Heerspink","year":"2024","unstructured":"Heerspink, H. J. L. et al. A meta-analysis of randomized controlled clinical trials for implications of acute treatment effects on glomerular filtration rate for long-term kidney protection. Kidney Int. 106, 688\u2013698 (2024).","journal-title":"Kidney Int."},{"key":"4057_CR24","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1681\/ASN.0000000000000117","volume":"34","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink, H. J. L. et al. Change in albuminuria and GFR Slope as joint surrogate end points for kidney failure: implications for phase 2 clinical trials in CKD. J. Am. Soc. Nephrol. 34, 955\u2013968 (2023).","journal-title":"J. Am. Soc. Nephrol."},{"key":"4057_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110908","volume":"204","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink, H. J. L. et al. Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: the FINE-ONE trial. Diabetes Res. Clin. Pract. 204, 110908 (2023).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"4057_CR26","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41591-024-03327-6","volume":"31","author":"EM Apperloo","year":"2024","unstructured":"Apperloo, E. M. et al. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Nat. Med. 31, 278\u2013285 (2024).","journal-title":"Nat. Med."},{"key":"4057_CR27","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1681\/ASN.0000000000000418","volume":"35","author":"HJL Heerspink","year":"2024","unstructured":"Heerspink, H. J. L. et al. Effect of avenciguat on albuminuria in patients with CKD: two randomized placebo-controlled trials. J. Am. Soc. Nephrol. 35, 1227\u20131239 (2024).","journal-title":"J. Am. Soc. Nephrol."},{"key":"4057_CR28","doi-asserted-by":"crossref","unstructured":"Heerspink H. J. L., et al. The selective endothelin receptor antagonist SC0062 in IgA nephropathy: a randomized double-blind placebo-controlled clinical trial. J. Am. Soc. Nephrol. 36, 657\u2212667 (2025).","DOI":"10.1681\/ASN.0000000538"},{"key":"4057_CR29","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","volume":"403","author":"KR Tuttle","year":"2024","unstructured":"Tuttle, K. R. et al. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial. Lancet 403, 379\u2013390 (2024).","journal-title":"Lancet"},{"key":"4057_CR30","first-page":"1","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO).","year":"2013","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 3, 1\u2013150 (2013).","journal-title":"Kidney Int. Suppl."},{"key":"4057_CR31","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604\u2013612 (2009).","journal-title":"Ann. Intern. Med."},{"key":"4057_CR32","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.1002\/sim.9886","volume":"42","author":"W Collier","year":"2023","unstructured":"Collier, W., Haaland, B., Inker, L. & Greene, T. Handling missing within-study correlations in the evaluation of surrogate endpoints. Stat. Med. 42, 4738\u20134762 (2023).","journal-title":"Stat. Med."},{"key":"4057_CR33","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","volume":"175","author":"V Prasad","year":"2015","unstructured":"Prasad, V., Kim, C., Burotto, M. & Vandross, A. The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. JAMA Intern. Med. 175, 1389\u20131398 (2015).","journal-title":"JAMA Intern. Med."},{"key":"4057_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-024-02170-0","volume":"24","author":"W Collier","year":"2024","unstructured":"Collier, W., Haaland, B., Inker, L. A., Heerspink, H. J. L. & Greene, T. Comparing Bayesian hierarchical meta-regression methods and evaluating the influence of priors for evaluations of surrogate endpoints on heterogeneous collections of clinical trials. BMC Med. Res. Methodol. 24, 39 (2024).","journal-title":"BMC Med. Res. Methodol."},{"key":"4057_CR35","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2215\/CJN.0000000000000050","volume":"18","author":"W Collier","year":"2023","unstructured":"Collier, W. et al. Evaluation of variation in the performance of GFR slope as a surrogate end point for kidney failure in clinical trials that differ by severity of CKD. Clin. J. Am. Soc. Nephrol. 18, 183\u2013192 (2023).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"4057_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer, W. Conducting meta-analyses in R with the metafor package. J. Stat. Softw. 36, 1\u201348 (2010).","journal-title":"J. Stat. Softw."},{"key":"4057_CR37","unstructured":"R Core Team R: A Language and Environment for Statistical Computing (R Core Team, 2022)."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04057-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04057-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04057-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T15:03:27Z","timestamp":1769007807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04057-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4057"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-04057-z","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.J.L.H. has served as a consultant for AstraZeneca, Alexion, Amgen, Bayer, Boehringer Ingelheim, Biocity Biopharmaceutics, Dimerix, Eli Lilly, Novartis, Novo Nordisk, Roche and Travere Therapeutics and has received grant support from AstraZeneca, Bayer, Boehringer Ingelheim, Janssen and Novo Nordisk. W.H.C. reports funding from the National Kidney Foundation to his institute for his graduate research assistantship. G.B.A. reports funding for research studies through Columbia University, Calliditas, Travere Therapeutics, Novartis, Equillium, Roche, Sanofi, Reata, Apellis, Nephronet, Goldfinch and Vertex; consultancy for Sanofi-Genzyme, Roche\/Genentech, Apellis, Novartis, Travere Therapeutics, Calliditas, GlaxoSmithKline and Aurinia; and speaker for GlaxoSmithKline and Aurinia, both on lupus nephritis. J.F. reports lecture and consulting honoraria from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Calliditas, Fresenius, Novartis, Omeros, Travere Therapeutics and Vifor and membership on the data safety monitoring board in trials for Novo Nordisk A\/S and Visterra. E.I. received research funding and honoraria for lectures from AstraZeneca, Tanabe Mitsubishi, Boehringer Ingelheim, Daiichi-Sankyo, Kyowa Kirin and Novo Nordisk A\/S. J.B.L. is a consultant for CSL Behring and BioVie. P.K.T.L. received speaker honoraria from FibroGen, AstraZeneca and Baxter. B.D.M. is the National Leader in the ASCEND-D and ASCEND-ND trials of GlaxoSmithKline and the PROTECT and DUPLEX trials of Travere Therapeutics as well as a steering committee member in the Novartis APPLAUSE trial and the Vera Therapeutics ATACICEPT trial. B.L.N. has received fees for travel support, advisory boards, scientific presentations and steering committee roles from AstraZeneca, Alexion, Bayer, Boehringer Ingelheim, Cambridge Healthcare Research, Cornerstone Medical Education, the Limbic, Janssen, Medscape, Novo Nordisk and Travere Therapeutics, with all honoraria paid to The George Institute for Global Health. R.D.P. has been on steering committees for AbbVie* and Vertex*; has consulted for Otsuka*, Retex*, Estuary, SouffleTx, Sanofi-Genzyme, Regenephro and Regulus*; and is the section editor for cystic kidney disease for\n                      UpToDate\n                      (*paid to Tufts Medical Center). F.P.S. reports funding from the Italian Ministry of Health and the Italian Ministry of University and Research. C.W. reports lecture and consulting honoraria from Alexion, AstraZeneca, Bayer, Boehringer Ingelheim, CSL Vifor, GlaxoSmithKline, Novartis, Novo Nordisk and VeraTX. T.G. reports funding from the National Institutes of Health, the Patient Center Outcome Research Institute, the National Kidney Foundation and the Collaborative Study Group. L.A.I. reports funding to Tufts Medical Center from the National Institutes of Health, the National Kidney Foundation, Chinook, R3R, Otsuka, Alexion and Novartis; consulting agreements to Tufts Medical Center from Alexion and AstraZeneca; and consulting agreements from Dimerix. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}